2Q26 Results

RDsaúde

São Paulo, August 04, 2026. RD Saúde (Raia Drogasil S.A. – B3: RADL3) announces its results for the 2nd quarter of 2026 (2Q26). The Company's parent company and consolidated financial statements for the periods ended June 30, 2026 and 2025 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards – General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements, which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same period of the previous year.

IFRS 16: Our financial statements are prepared in accordance with IFRS 16. To better reflect the economic reality of the business, the figures presented in this report consider the pre-IFRS 16 standard with a reconciliation available in a dedicated section of this document.

HIGHLIGHTS:

- **PHARMACIES: 3.687 units in operation with 76 openings and 3 closures in the quarter;**
- **GROSS REVENUE: R$ 12.8 B, +18.3% growth and +10.9% MSSS, +8.1 pp above CMED;**
- **MARKET SHARE: 19.7% national share, a +1.7 pp increase with gains in every region;**
- **DIGITAL: R$ 3.9 B, +52.2% growth and retail penetration of 31.0%;**
- **ADJ. EBITDA: R$ 1.0 B, +17.9% & stable margin of 8.0%;**
- **ADJ. NET INCOME (WITH 4BIO)*: R$ 433 MM, +7.4% & margin of 3.4% (-0.3 pp);**
- **CASH FLOW: R$ 550 MM positive free cash flow, R$ 1,190 MM total cash generation incl. 4Bio;**
- **FINANCIAL LEVERAGE: 0.8x ND/EBITDA, a 0.5x YoY reduction.**

** Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.*

RADL3
R$ 18.85/share
Closing: Aug 03, 2026

MARKET CAP
R$ 33,0 billion

NUMBER OF SHARES
1,752,367,344

IR TEAM:
Flávio Correia
André Stolfi
Victor Torres
Felipe Correa

ir.rdsaude.com.br
ri@rdsaude.com.br

New consolidated summary (ex-4Bio)

In R$ thousands	2Q25	3Q25	4Q25	1Q26	2Q26
# of pharmacies	**3,371**	**3,453**	**3,547**	**3,614**	**3,687**
Organic openings	70	88	97	68	76
Closures	-	(6)	(3)	(1)	(3)
Headcount (EoP)	67,114	69,860	73,388	75,190	75,594
Pharmacist count (EoP)	13,734	13,981	14,377	14,965	15,199
# of tickets (thousands)	110,733	111,543	114,731	111,849	119,305
# of active customers (MM)	50.3	51.0	51.7	52.3	52.8
Gross revenue	**10,803,986**	**11,347,942**	**12,186,767**	**11,979,521**	**12,777,743**
Growth (YoY)	+13.1%	+15.5%	+22.3%	+20.4%	+18.3%
Gross profit	3,133,833	3,257,291	3,508,601	3,392,636	3,696,071
% of gross revenue	29.0%	28.7%	28.8%	28.3%	28.9%
Adjusted EBITDA	**862,980**	**892,592**	**924,318**	**820,786**	**1,017,348**
% of gross revenue	8.0%	7.9%	7.6%	6.9%	8.0%
Adj. net income (w/ 4Bio)	**402,744**	**401,986**	**361,654**	**299,752**	**432,729**
% of gross revenue	3.7%	3.5%	3.0%	2.5%	3.4%
Free cash flow	**(60,837)**	**615,609**	**(466,520)**	**284,869**	**549,989**

STORE DEVELOPMENT

Pharmacy count



	2Q25	3Q25	4Q25	1Q26	2Q26	LTM
Gross openings	+70	+88	+97	+68	+76	+329
Closures	-	-6	-3	-1	-3	-13
- Maturing	-	-	*-1*	-	-	*-1*
- Mature	-	*-6*	*-2*	*-1*	*-3*	*-12*
Net openings	+70	+82	+94	+67	+73	+316

Pharmacy portfolio

Age structure



We ended the 2Q26 with a total of 3,687 pharmacies in operation, opening 76 new units in 2Q26 and 329 LTM. We reiterate our guidance of 330-350 gross openings for 2026.

We closed 3 units in 2Q26 totaling 13 LTM, with only 1 still in the maturation process. This equates to a low error ratio of 0.3% of the LTM openings, highlighting the precision of our expansion process. The remaining 12 LTM closures were of mature units with an average of 13 years of operation, a result of the optimization of our portfolio, transferring revenues to our remaining nearby locations, releasing assets for efficient redeployment and eliminating fixed costs, thus increasing both the Company's EBITDA and ROIC.

At the end of 2Q26, a total of 25.0% of our pharmacies were still maturing and had not yet reached their full potential both in terms of revenue and profitability.

Number of cities with pharmacies



Pharmacies by region



Pharmacies by format



Our expansion continues to diversify our pharmacy network, both geographically and demographically. We have extended our presence to 684 cities in every state, +42 vs. the prior year, a unique capillarity in Brazilian retail under direct management.

We maintained a consistent expansion pace in São Paulo, our largest market, sustaining 32% of last year's expansion plan. Even with our broad presence in the state, we continue to identify meaningful opportunities and see solid performance from newly opened stores, reinforcing the potential to grow profitably across the country.

Finally, the IRR of new stores has been increasing, reflecting greater accuracy in expansion decisions, supported by recent efficiency gains in operations, by omnichannel performance, by the emerging GLP-1 market, among other factors.

Geographic presence



Retail Market Share

Quarterly share, customer prices, sell-out + sell-in



Source: IQVIA. Southeast excludes SP.

Our 3.7 thousand pharmacies are present in every state in the country and supported by an integrated network of 16 distribution centers, including the opening of the new DC in Itupeva/SP in April. This logistics grid allows us to serve more than 80% of our locations daily with lead times of up to 24 hours. As a result, we sustain high service levels, optimize working capital, and strengthen operational efficiency, establishing a significant competitive advantage.

Our national market share reached 19.7% in 2Q26, a robust gain of +1.7 pp vs. the prior year. In addition, we recorded relevant gains across all regions, demonstrating our competitive strength in diverse contexts and markets. Market shares reached 34.3% in São Paulo (+2.4 pp), 14.3% in the Southeast (+1.4 pp), 25.1% in the Midwest (+2.4 pp), 11.8% in the South (+0.7 pp), 14.4% in the Northeast (+1.4 pp), and 12.6% in the North (+1.6 pp).

We also achieved significant market share gains across all regions when excluding GLP-1 items and their substantial benefit to our figures.

DIGITAL, HEALTH AND CUSTOMER ENGAGEMENT

Digital sales and penetration

R$ millions, % of retail gross revenue



Digital channel mix

% of quarterly digital sales



81 de NPS
App rating
R$ 14.1 B
LTM digital sales

Delivery mix

% of quarterly digital sales



81 NPS
Delivery rating
1.1 B visits
Via apps and website LTM

We continued to advance our digital strategy, further strengthening our relationship with the customer. In the last 12 months, we recorded 1.1 billion visits across our digital channels, an impactful audience that enhances our role in promoting health. In addition, digitalization increases spending per customer, with digitally engaged loyal customers spending 30% more than the average loyal customer.

As a result, our digital channels reached R$ 3.9 billion in gross revenue in 2Q26, an absolute increase of R$ 1.4 billion and growth of +52% vs. the prior year. The share of digital channels reached 31.0% of retail sales, an increase of +6.1 pp.

We highlight the growing use of our apps, ensuring that customers enjoy the best mobile experience specialized in omnichannel health and wellness journeys. Digital sales through this channel increased +60% vs. the prior year, reaching an 83% share (+4 pp) of digital sales in the quarter.

This evolution in customer digitalization, leveraging our modern and proprietary channels, reflects the ongoing improvement of our mobile experience and a more complete, fully omnichannel health journey. It capitalizes on the capillarity of our store network, which has 95% of the A-Class population within a 1.5 km radius. This growing proximity, strengthened by our profitable organic expansion, constitutes another important competitive advantage by enabling 96% of digital orders to be delivered or picked up in less than 60 minutes with high economic efficiency.

Stix is another important source of differentiation through its customer loyalty ecosystem. We concluded on July 02, 2026 the acquisition of the remaining 67% of the company for R$ 23 million, with the first installment of R$ 2.3 million paid on the signing of the deal (May 20, 2026) and the remaining R$ 20.7 million on the closing of the deal (July 02, 2026). RD Saúde now holds 100% of Stix, ending its joint venture with GPA, but retaining them as a partner in the program. Founded in 2018, Stix has included RD Saúde as a minority shareholder with a 33.33% stake since 2019.

Stix operates in the structuring, development, operation and management of a loyalty program that brings together multiple partners and enables the accumulation, management and redemption of loyalty points. Stix is Brazil's largest customer loyalty ecosystem, ending 2Q26 with over 9.000 partner points of sale and a presence in every state. The coalition benefitted 15.0 million active customers in the last 12 months, with 6.7 million of them navigating within 2 or more partners. The acquisition of the company is aligned with RD Saúde's strategy to strengthen customer loyalty and engagement initiatives, while also simplifying Stix's corporate structure.

Finally, we continued to strengthen the role of our pharmacies in customers' integral health journey, positioning them as health hubs within the communities we serve and expanding engagement through pharmaceutical services. We now have 3.1 thousand units with *Mais Saúde* hubs and their expanded services portfolio, in addition to 442 units enabled for vaccination. In 2Q26, more than 1.9 million pharmaceutical services were performed, including CATs (clinical analysis tests), vaccinations, and other services, recording an NPS superior to the pharmacy average of 91.

GROSS REVENUES

Consolidated gross revenues



Retail sales mix



In a quarter without calendar effects, we ended 2Q26 with R$ 12,778 million in gross revenue, an 18.3% growth vs. the prior year.

We sustained a robust performance across all categories. Branded Rx grew +24.3% in the quarter, mainly driven by GLP-1 products. We highlight that the recent launching of new products in this category improves customer accessibility with volumes offsetting the reduction in average prices. Meanwhile, the other categories displayed a balanced performance among themselves: Generics grew +14.5%, OTC +13.0% and HPC +13.8% with a sequential acceleration of +2.1 pp vs. 1Q26.

Consolidated revenue growth | **Same-Store sales growth – Retail** | **Mature-Store sales growth – Retail**



Finally, we recorded average same-store sales growth of +12.5% in 2Q26. Among mature stores, which completed the full 3-year ramp-up, we posted an average growth of +10.9%, a pace 8.1 pp above the 2.8% CMED price adjustment authorized in 2026 and 6.3 pp above the LTM CPI. We highlight that, aligned with the market share gains, mature-store performance was robust in all regions, underscoring the elevated competitiveness of our brands within the different market environments.

GROSS PROFIT



* Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.

Gross profit totaled R$ 3,696.1 million in the quarter, equivalent to a gross margin of 28.9%. We recorded a 0.1 pp contraction vs. the prior year, driven by the higher penetration of GLP-1 products that carry a structurally lower gross margin, by the non-cash NPV adjustment, and by the lower annual inflationary gains on inventories, stemming from the lower average price adjustment authorized by CMED in 2026 (2.8%) vs. 2025 (3.1%). These pressures were almost entirely offset by commercial gains and by momentarily higher inventory losses in the 2Q25 comp base.

SELLING EXPENSES



Selling expenses totaled R$ 2,370.4 million in 2Q26, equivalent to 18.6% of gross revenue, a 0.2 pp pressure vs. the prior year.

We recorded pressures in personnel expenses, stemming from investments into our employee value proposition (EVP) since 4Q25, in last-mile deliveries and in other services. These were almost entirely offset by dilutions in rentals, payment methods and software licenses, in addition to operating leverage resulting from the strong mature-store sales growth above inflation.

GENERAL & ADMINISTRATIVE EXPENSES



General and administrative expenses totaled R$ 308.3 million in 2Q26, corresponding to 2.4% of gross revenue and a 0.3 pp dilution vs. the prior year. We recorded dilutions in personnel expenses, in addition to operating leverage resulting from the strong mature-store sales growth above inflation.

EBITDA



We recorded an adjusted EBITDA of R$ 1,017.3 million in 2Q26 with a stable EBITDA margin of 8.0% of gross revenue. The 17.9% increase vs. the prior year underscores the resilient nature of the Company, despite the challenging macro backdrop.

DEPRECIATION, NET FINANCIAL EXPENSES AND EBT

Adj. depreciation & amortization

R$ millions, % of gross revenue



Adj. net financial expenses

R$ millions, % of gross revenue



Adj. earnings before taxes*

R$ millions, % of gross revenue



* Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.

Adjusted depreciation expenses totaled R$ 277.1 million in 2Q26, equivalent to 2.2% of gross revenue, a dilution of 0.1 pp.

Adjusted net financial expenses totaled R$ 197.3 million in 2Q26, representing 1.5% of gross revenue, a dilution of 0.4 pp vs. the prior year. Of the total amount, R$ 131.8 million refer to the net financial interest accrued on financial liabilities, equivalent to 1.0% of gross revenue with a 0.3 pp reduction, driven by a lower average Selic rate and by R$ 15.8 million in financial revenue from the sale of 4Bio. Additionally, R$ 65.5 million refer to the non-cash NPV adjustment, equivalent to 0.5% of gross revenue with a 0.1 pp dilution.

Lastly, we recorded an adjusted EBT of R$ 542.7 million in 2Q26, a 33.4% increase vs. the prior year. This was equivalent to a margin of 4.2% of gross revenue with a 0.4 pp expansion.

INCOME TAXES AND NET INCOME

Adj. income tax and effective tax rate*

R$ millions, % of earnings before taxes



* Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.
** Effective tax rate.

Adjusted net income*

R$ millions, % of gross revenue



We provisioned a total of R$ 118.3 million in adjusted income tax in 2Q26, 0.9% of gross revenue, an increase of 0.3 pp vs. the prior year. The effective tax rate for 2Q26 was 21.8% of EBT, an increase of 6.3 pp. This increase was driven by the lower proportion of interest on equity provisioned in the quarter and by the retroactive one-off gain of R$ 11.5 million in the previous year from tax subventions in the state of Goiás. We estimate the recurring effective tax rate for 1H26 to be 19.1% of EBT.

Lastly, the 2Q26 adjusted consolidated net income, which only includes 1 month of 4Bio's discontinued operations, was of R$ 432.7 million, with a net margin of 3.4% of gross revenue. This equates to a 0.3 pp contraction vs. the prior year, which still included 3 months of 4Bio results. Excluding discontinued operations, adjusted net income was of R$ 424.4 million, a 23.4% growth vs. the prior year, with a net margin of 3.3% and a 0.1 pp expansion.

EBITDA & NET INCOME RECONCILIATION AND NON-RECURRING RESULTS

Adjusted EBITDA & Net Income Reconciliation (R$ millions)	2Q25	2Q26
Net income	**400.9**	**440.0**
Results of discontinued operations (4Bio)	(58.7)	(8.3)
Income tax	62.0	122.0
Equity equivalence	0.5	0.2
Financial result	204.0	195.2
EBIT (ex-4Bio)	**608.6**	**749.1**
Depreciation and amortization	251.5	277.1
EBITDA (ex-4Bio)	**860.2**	**1,026.2**
Asset write-offs	(0.9)	7.0
Social investments and donations	11.2	5.0
Tax effects from previous years	(2.3)	(6.8)
Other non-recurring/non-operating effects	(5.2)	(14.1)
Adjusted EBITDA (ex-4Bio)	**863.0**	**1,017.3**
Net income	**400.9**	**440.0**
Net non-rec. effects of discont. operations (4Bio)	0.0	0.0
Non-recurring EBITDA effects	2.8	(8.9)
Non-recurring financial revenues	-	(2.2)
Non-rec. effects of cont. op. on income taxes (34%)	(1.0)	3.7
Adjusted net income	**402.7**	**432.7**

Within our EBITDA, we recorded R$ 8.9 million in net non-recurring revenues in the 2Q26. This includes expenses of R$ 7.0 million in asset write-offs and R$ 5.0 million in social investments & donations, as well as revenues of R$ 6.8 million in gains related to tax effects of previous years and R$ 14.1 million in other non-recurring effects, primarily related to investees. In net income, we recorded R$ 2.2 million non-recurring financial revenues and R$ 3.7 million in income taxes from the non-recurring effects.

CASH CYCLE

Cash cycle*



* Adjusted for discounted receivables & advanced payments to suppliers.

We recorded a cash cycle of 51.7 days in 2Q26, a reduction of 10.7 days compared to the same period of last year, adjusted for discounted receivables and advanced payments to suppliers and including the positive effects derived from the end of the ICMS-ST tax regime in the state of São Paulo. This improvement was driven primarily by an increase of 10.9 days in suppliers and a decrease of 1.2 days in inventories, more than offsetting an increase of 1.4 days in receivables.

CASH FLOW

Cash flow (R$ millions)	2Q25 Ex-4Bio	2Q26
Adjusted EBIT	**611.4**	**740.2**
NPV adjustment	(65.5)	(56.6)
Non-recurring effects	(2.8)	11.0
Income tax (34%)	(184.7)	(236.2)
Depreciation	251.3	277.2
Impairment provision (4Bio)	-	6.7
Others	(14.6)	67.5
Resources from operations	**595.2**	**809.9**
Cash cycle*	(333.5)	(71.2)
Other assets (liabilities)**	(6.9)	140.7
Operating cash flow	**254.8**	**879.4**
Investments	(315.6)	(329.4)
Free cash flow	**(60.8)**	**550.0**
Investment activities in investees	(17.9)	227.4
Interest on equity and dividends	(308.3)	(246.3)
Income tax paid over interest on equity	(15.4)	(23.3)
Net financial expenses***	(143.8)	(131.8)
Tax benefit (fin. exp., IoE, dividends)	93.7	97.4
Total cash flow (ex-4Bio)	**(452.6)**	**473.2**
Effects from discontinued operations (4Bio)	95.3	716.4
Total (including 4Bio effects)	**(357.2)**	**1,189.7**

*Includes adjustments to discounted receivables. **Incl. NPV. ***Excl. NPV.

We generated R$ 809.9 million in resources from operations in 2Q26 (6.3% of gross revenue) with an operating cash flow of R$ 879.4 million. We generated R$ 69.5 million in working capital and invested R$ 329.4 million in CAPEX, with R$ 144.3 million allocated to the opening of new pharmacies, R$ 85.3 million to maintenance and renovation of existing units, R$ 74.1 million to technology, R$ 18.1 million to logistics, and R$ 7.8 million to other projects. In investees, we recorded R$ 144.5 million from the incorporated cash position of Stix and of R$ 100.0 million from the first installment for the sale of 4Bio, as well as R$ 716,4 million for the remainder of the deal.

Net financial expenses resulted in a cash outflow of R$ 131.8 million in 2Q26. These expenses were partially offset by a tax deduction of R$ 97.4 million related to financial expenses and interest on equity (IoE). Finally, we announced R$ 154.5 million in IoE and R$ 47.6 million in dividends in 2Q26, compared with R$ 131.8 million in IoE and R$ 104.0 million in dividends in 2Q25.

INDEBTEDNESS

Net debt (R$ millions)	2Q25	3Q25	4Q25	1Q26	2Q26
Short-term debt	849.7	522.5	508.1	425.5	365.3
Long-term debt	2,758.6	2,760.1	3,359.6	3,236.1	3,087.4
Total gross debt	**3,608.3**	**3,282.6**	**3,867.8**	**3,661.5**	**3,452.6**
(-) Cash and equivalents	376.3	339.6	358.6	441.8	536.5
Net debt	**3,232.0**	**2,943.0**	**3,509.1**	**3,219.7**	**2,916.1**
Discounted receivables	761.2	514.7	800.3	953.6	808.9
Advances to suppliers	(13.2)	(3.7)	-	-	(25.7)
Sale of 4Bio - Pending receivables	-	-	-	-	(716.4)
Investment put/call options (estimated)	14.4	22.8	15.5	15.9	16.6
Adjusted net debt	**3,994.4**	**3,476.7**	**4,324.9**	**4,189.2**	**2,999.6**
LTM adjusted EBITDA	2,974.4	3,056.3	3,303.1	3,500.7	3,655.0
Adjusted net debt/LTM EBITDA	**1.3x**	**1.1x**	**1.3x**	**1.2x**	**0.8x**

We ended the 2Q26 with adjusted net debt of R$ 2,999.6 million, corresponding to a financial leverage ratio of 0.8x the adjusted EBITDA for the last 12 months, a 0.5x leverage reduction vs. the prior year. This reduction is comprised of 0.3x from the regular cash generation of operations and 0.2x from the sale of 4Bio.

Our adjusted net debt considers a balance of R$ 808.9 million in discounted receivables, of R$ 25.7 million in forward payments to suppliers, R$ 716.4 million in pending receivables related to the sale of 4Bio and R$ 16.6 million in obligations related to put/call options for remaining equity interests in investee companies.

Gross debt totaled R$ 3,452.6 million, fully comprised by the issuance of Debentures and Real Estate Receivables Certificates (CRIs), all with a reaffirmed AAA.br rating from Moody's. Of total indebtedness, 89% is long-term and 11% is short-term. We ended the quarter with a total cash and equivalents position of R$ 536.5 million.

Despite a low leverage of 0.8x, we highlight that we expect additional cash generation over time from the sale of 4Bio and from the recovery of ICMS-ST taxes from inventories in the state of São Paulo.

TOTAL SHAREHOLDER RETURNS



Our share price decreased 26.1% in 2Q26, while the IBOVESPA decreased by 8.5%. During the period, the average daily trading volume (ADTV) was R$ 220 million.

Since the IPO of Drogasil in June 2007, we achieved a cumulative share appreciation of 2,023%, compared to only 216% for the IBOVESPA. Including the payment of interest on equity and dividends, we generated an average annual total return to shareholders of 18.3%.

Considering the IPO of Raia in December 2010, the cumulative return amounted to 512%, compared to 153% for the IBOVESPA. Including shareholder distributions, this equates to an average annual return of 13.4%.

IFRS-16

Since 2019, the financial statements have been prepared in accordance with IFRS 16. However, for historical comparability purposes, the figures presented in this report exclude the effects of this standard, as we believe the previous accounting approach better reflects the economic reality of our business. On RD Saúde's Investor Relations website (ir.rdsaude.com.br), the financial statements can be found in the 'Results Spreadsheets' section.

	2Q26		Change
Income Statement *(R$ millions)*	**Pre IFRS 16**	**IFRS 16**	**Δ 2Q26**
Gross Revenue	**12,777.7**	**12,777.7**	**0.0**
Gross Profit	**3,696.1**	**3,697.7**	**1.7**
Gross Margin	28.9%	28.9%	0.0 pp
Selling Expenses	(2,370.4)	(2,013.0)	357.4
G&A	(308.3)	(307.6)	0.7
Total Expenses	**(2,678.7)**	**(2,320.6)**	**358.1**
as % of Gross Revenue	21.0%	18.2%	(2.8 pp)
Adjusted EBITDA	**1,017.3**	**1,377.1**	**359.8**
as % of Gross Revenue	8.0%	10.8%	2.8 pp
Non-Recurring Expenses / Revenues	8.9	9.6	0.8
Depreciation and Amortization	(277.1)	(532.5)	(255.4)
Financial Results	(195.2)	(323.7)	(128.5)
Income Tax	(122.0)	(114.1)	8.0
Net income ex-4Bio	**431.7**	**416.3**	**(15.4)**
as % of Gross Revenue	3.4%	3.3%	(0.1 pp)
Net Income	**440.0**	**424.5**	**(15.4)**
as % of Gross Revenue	3.4%	3.3%	(0.1 pp)

Balance Sheet *(R$ millions)*	2Q26 Pre IFRS 16	2Q26 IFRS 16	Change Δ 2Q26
Assets	**20,154.5**	**24,822.6**	**4,668.1**
Current Assets	**14,251.7**	**14,251.7**	**(0.0)**
Non-Current Assets	**5,902.7**	**10,570.9**	**4,668.1**
Income Tax and Social Charges deferred	51.0	255.7	204.7
Other Credits	541.6	541.1	(0.4)
Investments	0.2	0.0	(0.2)
Right of use	0.0	4,464.1	4,464.1
Liabilities and Shareholder's Equity	**20,154.5**	**24,822.6**	**4,668.1**
Current Liabilities	**9,116.2**	**10,135.7**	**1,019.6**
Financial Leases	0.0	1,025.3	1,025.3
Other Accounts Payable	593.7	588.0	(5.7)
Non-Current Liabilities	**3,304.4**	**7,396.1**	**4,091.7**
Financial Leases	0.0	4,115.1	4,115.1
Income Tax and Social Charges Deferred	23.4	0.0	(23.4)
Shareholder's Equity	**7,733.9**	**7,290.8**	**(443.1)**
Income Reserves	2,489.1	2,075.7	(413.4)
Accrued Income	261.0	231.4	(29.7)
Equity Adjustments	63.0	63.0	(0.1)

Cash Flow *(R$ millions)*	2Q26 Pre IFRS 16	2Q26 IFRS 16	Change Δ 2Q26
Adjusted EBIT	**740.2**	**844.6**	**104.4**
Non-Recurring Effects	11.0	9.6	(1.4)
Income Tax (34%)	(236.2)	(271.2)	(35.0)
Depreciation	277.2	532.5	255.3
Rental Expenses	0.0	(358.9)	(358.9)
Others	67.5	109.8	42.3
Resources from Operations	**809.9**	**816.6**	**6.7**
Operating Cash Flow	**879.4**	**879.4**	**0.0**
Investments	**(329.4)**	**(329.4)**	**0.0**
Free Cash Flow	**550.0**	**550.0**	**0.0**
Total cash flow (ex-4Bio)	**473.2**	**473.2**	**0.0**
Total cash flow (with 4Bio)	**1,189.7**	**1,189.7**	**0.0**

RESULTS CONFERENCE CALL

August 05th 2026, 10:00 AM (BRT),
with simultaneous translation to English.

Access link
https://www.resultadosrdsaude.com.br/

For more information, please contact our Investor Relations department: ri@rdsaude.com.br

Consolidated adjusted income statement (R$ thousands)	**2Q25** Resubmitted	**2Q26**
Gross revenue	**10,803,986**	**12,777,743**
Taxes, deductions and returns	(729,303)	(1,715,344)
Net revenue	**10,074,683**	**11,062,399**
Cost of goods sold	(6,940,850)	(7,366,328)
Gross profit	**3,133,833**	**3,696,071**
Selling expenses	(1,982,851)	(2,370,424)
General and administrative expenses	(288,002)	(308,299)
Operational expenses	**(2,270,853)**	**(2,678,723)**
Adjusted EBITDA	**862,980**	**1,017,348**
Depreciation and amortization	(251,535)	(277,134)
Operational earnings before financial results	**611,445**	**740,214**
Financial expenses	(310,428)	(336,869)
Financial revenue	106,401	139,545
Financial results	**(204,027)**	**(197,324)**
Equity equivalence	(467)	(180)
Earnings before income tax and social charges	**406,951**	**542,709**
Income tax and social charges	(62,941)	(118,284)
Adjusted net income ex-4Bio	**344,011**	**424,425**
Results of discontinued operations (4Bio)	58,734	8,304
Adjusted net income	**402,744**	**432,729**

Consolidated income statement	2Q25	2Q26
(R$ thousands)	Resubmitted	
Gross revenue	**10,803,986**	**12,777,743**
Taxes, deductions and returns	(729,303)	(1,715,344)
Net revenue	**10,074,683**	**11,062,399**
Cost of goods sold	(6,940,850)	(7,366,328)
Gross profit	**3,133,833**	**3,696,071**
Selling expenses	(1,982,851)	(2,370,424)
General and administrative expenses	(288,002)	(308,299)
Other operational expenses, net	(2,796)	8,850
Operational expenses	**(2,273,649)**	**(2,669,873)**
EBITDA	**860,184**	**1,026,198**
Depreciation and amortization	(251,535)	(277,134)
Operational earnings before financial results	**608,649**	**749,064**
Financial expenses	(310,428)	(336,869)
Financial revenue	106,401	141,705
Financial results	**(204,027)**	**(195,165)**
Equity equivalence	(467)	(180)
Earnings before income tax and social charges	**404,156**	**553,719**
Income tax and social charges	(61,990)	(122,028)
Net income ex-4Bio	**342,166**	**431,691**
Results of discontinued operations (4Bio)	58,689	8,287
Net income	**400,855**	**439,978**

Assets (R$ thousands)	2Q25	2Q26
Cash and cash equivalents	376,334	536,500
Financial investments	78,278	116,449
Accounts receivable	2,373,076	3,095,748
Inventories	7,948,264	8,333,897
Taxes receivable	436,987	1,066,713
Anticipated expenses	151,808	156,290
Judicial deposits	4,060	3,782
Assets of investment for sale (4Bio)	1,658,025	-
Other accounts receivable	609,794	942,368
Current assets	13,636,626	14,251,747
Deposit in court	32,718	64,898
Taxes receivable	225,666	236,634
Income tax and social charges deferred	48,182	51,012
Other credits	14,928	541,551
Investments	13,447	186
Property, plant and equipment	2,737,578	2,970,046
Intangible	2,036,972	2,038,393
Non-current assets	5,109,491	5,902,720
TOTAL ASSETS	**18,746,118**	**20,154,467**

Liabilities and shareholder equity (R$ thousands)	2Q25	2Q26
Suppliers	5,192,141	6,375,302
Loans and financing	849,691	365,266
Salaries and social charges payable	777,866	925,554
Taxes payable	384,088	508,068
Dividends and interest on equity	217,181	306,115
Provision for lawsuits	77,279	42,116
Liabilities of investment for sale (4Bio)	796,567	-
Other accounts payable	415,224	593,734
Current liabilities	8,710,038	9,116,156
Loans and financing	2,758,638	3,087,383
Provision for lawsuits	102,133	145,181
Income tax and social charges deferred	25,503	23,417
Other accounts payable	77,625	48,458
Non-current liabilities	2,963,899	3,304,440
Common stock	4,000,000	4,750,000
Capital reserves	131,107	159,823
Revaluation reserve	11,022	10,895
Income reserves	2,529,320	2,489,084
Accrued income	322,824	261,046
Equity adjustments	62,969	63,023
Non controller interest	14,939	-
Shareholder equity	7,072,180	7,733,871
TOTAL LIABILITIES & SHAREHOLDER EQUITY	**18,746,118**	**20,154,467**

Cash Flow (with 4Bio)	2Q25	2Q26
(R$ thousands)		
Earnings before Income Tax and Social Charges	**427,170**	**553,718**
Adjustments		
Depreciation and Amortization	252,432	277,204
Compensation plan with restricted shares, net	13,213	10,819
Interest over additional stock option	467	723
PP&E and Intangible Assets residual value	1,016	54,020
Provisioned Lawsuits	(10,330)	20,579
Provisioned Inventory Loss	(19,142)	(5,535)
Provision for Doubtful Accounts	9,063	2,709
Provisioned Store Closures	(310)	4,492
Interest Expenses	125,090	125,301
Debt Issuance Costs Amortization	2,444	1,917
Equity Equivalence Result	434	180
Gains from business combination	-	(19,568)
Provision for realization of recoverable investment	-	6,698
	801,547	**1,033,257**
Assets and Liabilities variation		
Clients and Other Accounts Receivable	(208,850)	(263,318)
Inventories	296,920	112,545
Other Short Term Assets	(116,409)	(144,793)
Suppliers	(403,675)	(90,789)
Salaries and Social Charges	133,527	177,082
Taxes Payable	(13,557)	52,356
Other Liabilities	(99,620)	(84,754)
Rents Payable	6,032	27,094
Cash from Operations	**395,915**	**818,679**
Interest Paid	(94,936)	(186,025)
Income Tax and Social Charges Paid	(26,165)	-
Paid lawsuits	(8,020)	(33,918)
Net Cash from (invested) Operational Activities	**266,794**	**598,736**
Investment Activities Cash Flow		
Cash acquired from business combination	-	144,517
PP&E and Intangible Acquisitions	(323,410)	(324,281)
PP&E Sale Payments	-	533
Restricted Investments	(12,484)	(20,515)
Acquisitions and capital contributions in investments, net	-	(2,300)
Cash from divestments	-	100,000
Net Cash from Investment Activities	**(335,894)**	**(102,046)**
Financing Activities Cash Flow		
Funding	500,000	-
Payments	-	(150,000)
Interest on Equity and Dividends Paid	(308,261)	(246,301)
Senior Quota Redemptions	-	(5,691)
Net Cash from Funding Activities	**191,739**	**(401,992)**
Cash and equivalents in the beggining of the period (with 4Bio)	**404,381**	**441,801**
Cash and equivalents net increase (with 4Bio)	122,639	94,698
Cash and equivalents in the end of the period (with 4Bio)	**527,020**	**536,500**